CBLL vs PHG vs HTFL Stock Comparison

Ceribell, Koninklijke Philips and Heartflow Prices as of Nov 2, 2026 Peers: Industry group
1 more company in this comparison (OSUR) Create a free account to keep reading and compare up to 10 companies.
CBLL Ceribell, Inc.
$26.96 +13.8% 1M +136.5% 1Y
Market cap
$1.08B
P/E
–
Revenue (TTM)
$108.72M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins
PHG Koninklijke Philips Nv
$27.58 +15.3% 1M +1.0% 1Y
Market cap
$29.35B
P/E
15.4x
Revenue (TTM)
$30.13B
Div. yield
–
Diagnostic Equipment Healthcare
4 wins
HTFL Heartflow, Inc.
$54.45 +10.4% 1M +46.5% 1Y
Market cap
$4.93B
P/E
–
Revenue (TTM)
$212.08M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

7 decided of 12

Koninklijke Philips leads on 4 of the 12 questions below (Koninklijke Philips 4, Ceribell 2, Heartflow 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCBLLPHGHTFLLeader
Larger companyMarket capitalisation $1.08B $29.35B $4.93B PHG
Cheaper on earningsLower P/E, profitable companies only -14.6x 15.4x -41.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 14.4x — –
Faster revenue growthRevenue growth, trailing twelve months +31.7% +6.1% +42.5% HTFL
More profitableNet margin, trailing twelve months -64.7% 8.9% -49.4% PHG
Better return on capitalReturn on invested capital — 11.5% — –
Less leveragedLower net debt / EBITDA 1.6x 1.8x — CBLL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +136.5% +1.0% +46.5% CBLL
Better 5-year returnAnnualised price return, 5 years — -10.3%/yr — –
Less volatileAnnualised volatility, 1 year 51.8% 28.4% 76.8% PHG
Higher overall scoreMean of the five percentile scores vs peers 38/100 80/100 55/100 PHG

Percentile Scorecard

CBLLPHGHTFL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCBLLPHGHTFL
Valuation 22 #177 of 227 98 #6 of 227 9 #207 of 227
Growth 20 #176 of 220 96 #9 of 220 74 #59 of 220
Profitability 37 #133 of 209 96 #9 of 209 48 #110 of 209
Financial Health 82 #45 of 240 31 #167 of 240 92 #21 of 240
Shareholder Returns 31 #96 of 138 80 #29 of 138 –
Overall 38 80 55
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics
  • PHG ranked among 247 companies in Medical Devices and Diagnostics
  • HTFL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCBLLPHGHTFLSPY
1 month +13.8%+15.3%+10.4% -2.3%
3 months +47.2%+5.1%+103.5% -0.7%
6 months +33.0%+5.1%+88.1% +4.8%
Year to date +22.9%+1.8%+86.8% +10.3%
1 year +136.5%+1.0%+46.5% +10.3%
3 years —+34.2%— +73.0%
3 years, per year —+10.3%— +20.1%
5 years —-42.0%— +61.9%
5 years, per year —-10.3%— +10.1%
10 years —-7.1%— +258.6%
10 years, per year —-0.7%— +13.6%

Risk

MeasureCBLLPHGHTFLSPY
Volatility, 1Y 51.8%28.4%76.8% 12.8%
Downside volatility, 1Y 49.2%27.8%78.0% 12.8%
Beta vs S&P 500, 1Y 1.200.801.91 1.00
Return / volatility, 1Y 2.640.030.61 0.80
Max drawdown, 5Y -63.9%-75.6%-48.7% -25.4%
From 52-week high -3.1%-16.2%-10.0% -3.5%
52-week high $27.82$32.91$60.53 $779.14
52-week low $10.92$23.81$20.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCBLLPHGHTFL
P/E now vs peer median -15.5xmedian 28.4x 14.2xmedian 28.4x -47.0xmedian 28.4x
P/S now vs peer median 10.1xmedian 3.0x 1.3xmedian 3.0x 23.3xmedian 3.0x
EV/EBITDA now vs peer median -13.5xmedian 18.0x 8.3xmedian 18.0x —median 18.0x
P/FCF now vs peer median -18.8xmedian 25.0x 6.1xmedian 25.0x —median 25.0x
P/B now vs peer median 8.0xmedian 2.3x 2.0xmedian 2.3x 16.9xmedian 2.3x
PEG now vs peer median —median 0.93 0.34median 0.93 —median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCBLLPHGHTFL
Revenue $108.72M $30.13B $212.08M
Gross profit $97.04M $16.13B $169.83M
Operating income -$75.87M $2.79B -$80.25M
Net income -$73.88M $1.45B -$118.37M
Free cash flow -$56.43M $5.23B -$59.18M
R&D $25.37M $1.99B $83.84M
EPS (diluted) $-1.92 $1.98 $-1.37
Cash & equivalents $41.99M $3.12B $34.36M
Total debt $20.00M $9.23B –
Shares (diluted) 38.50M 962.50M 86.40M
Enterprise value $529.67M $17.62B $4.68B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCBLLPHGHTFL
P/E -15.5x 14.2x -47.0x
P/FCF -18.8x 6.1x –
P/Operating cash flow -19.1x 10.0x –
P/S 10.1x 1.3x 23.3x
P/B 8.0x 2.0x 16.9x
P/Tangible book 8.0x 2.6x 16.9x
EV/EBITDA -13.5x 8.3x –
EV/EBIT -13.2x 12.8x -69.4x
EV/Revenue 9.0x 1.6x 22.1x
EV/FCF -16.8x 7.8x –
EV/Operating cash flow -17.0x 12.8x –
PEG (3Y EPS CAGR) – 0.34 –

Growth

14 metrics
MetricCBLLPHGHTFL
Revenue growth (1Y) 31.7% 6.1% 42.5%
Revenue CAGR (3Y) – 2.3% –
Gross profit growth (1Y) 33.4% 82.4% 48.8%
Gross profit CAGR (3Y) – 6.7% –
Operating income growth (1Y) -34.6% 121.3% -9.5%
Operating income CAGR (3Y) – 52.0% –
Net income growth (1Y) -33.6% 293.5% -18.3%
Net income CAGR (3Y) – 35.6% –
EPS growth (1Y) -27.5% 539.4% 91.4%
EPS CAGR (3Y) – 42.2% –
Operating cash flow growth (1Y) -44.3% 116.7% –
Operating cash flow CAGR (3Y) – 53.6% –
Free cash flow growth (1Y) -41.8% 54.2% –
Free cash flow CAGR (3Y) – 45.6% –

Profitability

14 metrics
MetricCBLLPHGHTFL
Gross margin 88.9% 77.8% 79.1%
EBITDA margin -67.1% 19.8% –
Operating margin -68.6% 12.9% -31.8%
Pretax margin -64.7% 11.9% -49.4%
Net margin -64.7% 8.9% -49.4%
FCF margin -53.7% 21.1% –
Operating cash flow margin -53.0% 12.9% –
Return on equity -49.0% 12.7% -34.5%
Return on assets -38.3% 5.4% -28.5%
Return on invested capital – 11.5% –
Return on capital employed -45.1% 11.8% -20.9%
Asset turnover 0.6x 0.7x 0.6x
Cash conversion (OCF / net income) 0.8x 1.9x –
Stock comp / revenue 16.1% 0.7% 9.6%

Financial Health

11 metrics
MetricCBLLPHGHTFL
Debt / assets 12.0% 31.2% –
Debt / equity 0.2x 0.7x –
Net debt / EBITDA 1.6x 1.8x –
Debt / FCF -0.4x 2.2x –
Liabilities / assets 22.9% 57.1% 18.8%
Equity / assets 77.1% 42.9% 81.2%
Interest coverage -38.6x 6.2x –
Current ratio 9.2x 1.3x 5.1x
Quick ratio 8.6x 0.7x 6.6x
Cash ratio 7.5x 0.2x 5.6x
Altman Z-score 14.31 – 39.77

Shareholder Returns

7 metrics
MetricCBLLPHGHTFL
Dividend yield – 3.6% –
Net buyback yield -0.6% -0.5% –
Shareholder yield -0.6% 3.1% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCBLLPHGHTFL
Forward P/E – 14.4xFY2026 –
EPS, next fiscal year $-1.86FY2026 $1.98FY2026 $-0.43FY2026
EPS growth, next FY – +6.5%FY2026 –
EPS growth, the year after – -10.1% –
Revenue, next fiscal year $118.32MFY2026 $21.63BFY2026 $261.38MFY2026
Revenue growth, next FY +32.9%FY2026 +1.8%FY2026 +48.5%FY2026
Revenue growth, the year after +21.1% -8.2% +20.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCBLLPHGHTFL
Held by institutions 79.9% 5.4% 100.0%
Institutions holding 124 365 193
Change in shares held, QoQ +2.2% +0.8% +133.0%
Institutions buying 74 268 140
Institutions selling 36 76 38
Buyers to sellers 2.06 3.53 3.68

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CBLLPHGHTFL
CBLL 1.00 0.24 0.25
PHG 0.24 1.00 0.13
HTFL 0.25 0.13 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CBLL, PHG and HTFL?

Koninklijke Philips (PHG) is the largest by market capitalisation: Ceribell (CBLL) $1.08B, Koninklijke Philips (PHG) $29.35B, Heartflow (HTFL) $4.93B.

Which company is growing faster?

Heartflow (HTFL) grew revenue fastest over the trailing twelve months: Ceribell (CBLL) +31.7%, Koninklijke Philips (PHG) +6.1%, Heartflow (HTFL) +42.5%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Ceribell (CBLL) -64.7%, Koninklijke Philips (PHG) 8.9%, Heartflow (HTFL) -49.4%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Ceribell (CBLL) +136.5%, Koninklijke Philips (PHG) +1.0%, Heartflow (HTFL) +46.5%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Ceribell (CBLL) 51.8%, Koninklijke Philips (PHG) 28.4%, Heartflow (HTFL) 76.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CBLL, PHG and HTFL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.